Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension

Luciana Neves Cosenso-Martin, Lais Yumi Takaoka, Jose Fernando Vilela-Martin Internal Medicine Division, State Medical School at Sao Jose do Rio Preto (FAMERP), Hospital de Base, Sao Jose do Rio Preto, Sao Paulo, BrazilCorrespondence: Jose Fernando Vilela-MartinState Medical School at Sao Jose do Ri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cosenso-Martin LN, Takaoka LY, Vilela-Martin JF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	type 2 diabetes hypertension glycemic variability vascular endothelium dipeptidyl-peptidase iv inhibitors arterial stiffness Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/b35bd148569741d0b3a3712e6c77151a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b35bd148569741d0b3a3712e6c77151a
record_format	dspace
spelling	oai:doaj.org-article:b35bd148569741d0b3a3712e6c77151a2021-12-02T09:18:20ZRandomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension1178-7007https://doaj.org/article/b35bd148569741d0b3a3712e6c77151a2020-09-01T00:00:00Zhttps://www.dovepress.com/randomized-study-comparing-vildagliptin-vs-glibenclamide-on-glucose-va-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Luciana Neves Cosenso-Martin, Lais Yumi Takaoka, Jose Fernando Vilela-Martin Internal Medicine Division, State Medical School at Sao Jose do Rio Preto (FAMERP), Hospital de Base, Sao Jose do Rio Preto, Sao Paulo, BrazilCorrespondence: Jose Fernando Vilela-MartinState Medical School at Sao Jose do Rio Preto (FAMERP), Hospital de Base, Ave Brig. Faria Lima 5416, Sao Jose do Rio Preto, Sao Paulo 15090-000, BrazilTel +55 17 32015727Email vilelamartin@uol.com.brBackground: Glucose variability (GV) is considered an important factor for cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM). High GV causes endothelial dysfunction and increased oxidative stress. Dipeptidyl peptidase-4 (DPP-4) inhibitors may improve endothelial function and decrease GV. The aim of this study was to investigate the effects of vildagliptin, a DPP-4 inhibitor, compared with glibenclamide in GV and endothelial function in patients with T2DM and arterial hypertension.Methods: This is a prospective, randomized, open and drug-controlled study. Fifty patients older than 35 years with T2DM and hypertension without CVD were randomized to receive vildagliptin (n=25) or glibenclamide (n=25), both in added-on metformin. Laboratory tests and analysis of endothelial function were performed before and 12 weeks after treatment. Endothelial function, defined by reactive hyperemia index (RHI), was analyzed by peripheral artery tonometry (endo-PAT2000). GV was evaluated by capillary glucose with intermittent monitoring device, six measurements per day, for three days, before and after treatment. The median of standard deviation (SD) of mean blood glucose (MBG) was used to evaluate GV.Results: GV decreased in the vildagliptin group (35.2 to 30.7, P=0.037) but did not change with glibenclamide (37.6 to 37.5, P=0.765). Glycated hemoglobin was similar in both groups. MBG decreased only in glibenclamide group, without difference with vildagliptin group (P=0.374). There were no changes in the RHI in both groups and there was no correlation between GV and RHI (P=0.658).Conclusion: Vildagliptin reduces GV; however, the action on endothelial function was not demonstrated. In addition, there was no correlation between GV and endothelial function.Keywords: type 2 diabetes, hypertension, glycemic variability, vascular endothelium, dipeptidyl-peptidase IV inhibitors, arterial stiffnessCosenso-Martin LNTakaoka LYVilela-Martin JFDove Medical Pressarticletype 2 diabeteshypertensionglycemic variabilityvascular endotheliumdipeptidyl-peptidase iv inhibitorsarterial stiffnessSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 3221-3229 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes hypertension glycemic variability vascular endothelium dipeptidyl-peptidase iv inhibitors arterial stiffness Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes hypertension glycemic variability vascular endothelium dipeptidyl-peptidase iv inhibitors arterial stiffness Specialties of internal medicine RC581-951 Cosenso-Martin LN Takaoka LY Vilela-Martin JF Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
description	Luciana Neves Cosenso-Martin, Lais Yumi Takaoka, Jose Fernando Vilela-Martin Internal Medicine Division, State Medical School at Sao Jose do Rio Preto (FAMERP), Hospital de Base, Sao Jose do Rio Preto, Sao Paulo, BrazilCorrespondence: Jose Fernando Vilela-MartinState Medical School at Sao Jose do Rio Preto (FAMERP), Hospital de Base, Ave Brig. Faria Lima 5416, Sao Jose do Rio Preto, Sao Paulo 15090-000, BrazilTel +55 17 32015727Email vilelamartin@uol.com.brBackground: Glucose variability (GV) is considered an important factor for cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM). High GV causes endothelial dysfunction and increased oxidative stress. Dipeptidyl peptidase-4 (DPP-4) inhibitors may improve endothelial function and decrease GV. The aim of this study was to investigate the effects of vildagliptin, a DPP-4 inhibitor, compared with glibenclamide in GV and endothelial function in patients with T2DM and arterial hypertension.Methods: This is a prospective, randomized, open and drug-controlled study. Fifty patients older than 35 years with T2DM and hypertension without CVD were randomized to receive vildagliptin (n=25) or glibenclamide (n=25), both in added-on metformin. Laboratory tests and analysis of endothelial function were performed before and 12 weeks after treatment. Endothelial function, defined by reactive hyperemia index (RHI), was analyzed by peripheral artery tonometry (endo-PAT2000). GV was evaluated by capillary glucose with intermittent monitoring device, six measurements per day, for three days, before and after treatment. The median of standard deviation (SD) of mean blood glucose (MBG) was used to evaluate GV.Results: GV decreased in the vildagliptin group (35.2 to 30.7, P=0.037) but did not change with glibenclamide (37.6 to 37.5, P=0.765). Glycated hemoglobin was similar in both groups. MBG decreased only in glibenclamide group, without difference with vildagliptin group (P=0.374). There were no changes in the RHI in both groups and there was no correlation between GV and RHI (P=0.658).Conclusion: Vildagliptin reduces GV; however, the action on endothelial function was not demonstrated. In addition, there was no correlation between GV and endothelial function.Keywords: type 2 diabetes, hypertension, glycemic variability, vascular endothelium, dipeptidyl-peptidase IV inhibitors, arterial stiffness
format	article
author	Cosenso-Martin LN Takaoka LY Vilela-Martin JF
author_facet	Cosenso-Martin LN Takaoka LY Vilela-Martin JF
author_sort	Cosenso-Martin LN
title	Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
title_short	Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
title_full	Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
title_fullStr	Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
title_full_unstemmed	Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
title_sort	randomized study comparing vildagliptin vs glibenclamide on glucose variability and endothelial function in patients with type 2 diabetes mellitus and hypertension
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/b35bd148569741d0b3a3712e6c77151a
work_keys_str_mv	AT cosensomartinln randomizedstudycomparingvildagliptinvsglibenclamideonglucosevariabilityandendothelialfunctioninpatientswithtype2diabetesmellitusandhypertension AT takaokaly randomizedstudycomparingvildagliptinvsglibenclamideonglucosevariabilityandendothelialfunctioninpatientswithtype2diabetesmellitusandhypertension AT vilelamartinjf randomizedstudycomparingvildagliptinvsglibenclamideonglucosevariabilityandendothelialfunctioninpatientswithtype2diabetesmellitusandhypertension
_version_	1718398205821976576

Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension

Ejemplares similares